Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine With Induction Chemotherapy in AML
NCT01627041Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2011
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Complete remission rate (CR1). Started Sep 2011; status: active, not recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01627041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627041.